|
Aug 5
|
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update
|
|
Jul 24
|
IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2025 for Phase 2 Clinical Trial of Neoadjuvant Darovasertib in Primary Uveal Melanoma
|
|
Jul 23
|
IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy
|
|
Jul 22
|
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
|
|
Jul 21
|
IDEAYA Biosciences to Participate in Upcoming July 2025 Investor Relations Event
|
|
Jun 26
|
General Mills upgraded, Trade Desk downgraded: Wall Street's top analyst calls
|
|
Apr 10
|
IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer
|
|
Feb 14
|
Down -8.63% in 4 Weeks, Here's Why You Should You Buy the Dip in IDEAYA Biosciences (IDYA)
|
|
Feb 13
|
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss
|
|
Feb 13
|
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
|
|
Feb 13
|
IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC
|
|
Feb 10
|
All You Need to Know About IDEAYA Biosciences (IDYA) Rating Upgrade to Buy
|
|
Feb 10
|
IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer
|
|
Dec 30
|
IDEAYA Biosciences Enters Into Licensing Agreement With Jiangsu Hengrui for Cancer Drug Candidate SHR-4849
|
|
Sep 24
|
IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans
|
|
Sep 23
|
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
|
|
Sep 22
|
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
|
|
Aug 26
|
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
|
Aug 1
|
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Jul 31
|
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
|